Bristol-Myers Squibb has formed a collaboration with ten of the world’s leading cancer research institutions which “aims to further the scientific understanding of immuno-oncology”.
The US drugs major has set up the International Immuno-Oncology Network (II-ON) which it says will focus on “the potential of harnessing the intelligence of the body’s own immune system to fight cancer”. The institutions who are participating in the collaboration include the Clinica Universidad Navarra in Pamplona, Spain, the UK’s Royal Marsden and the Institute of Cancer Research and the Netherlands Cancer Institute in Amsterdam.
On the other side of the Atlantic, B-MDS will also be working with the Dana-Farber Cancer Institute in Boston, Memorial Sloan-Kettering in New York and the University of Chicago.
Elliott Sigal, head of R&D at B-MS, said the II-ON “facilitates a public-private partnership that will leverage intellectual capabilities across a global network”.
